Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
72.67
Dollar change
+0.98
Percentage change
1.37
%
Index- P/E18.01 EPS (ttm)4.04 Insider Own0.00% Shs Outstand166.53M Perf Week3.30%
Market Cap12.10B Forward P/E18.27 EPS next Y3.98 Insider Trans- Shs Float166.52M Perf Month4.31%
Income672.65M PEG85.76 EPS next Q0.95 Inst Own14.50% Short Float0.70% Perf Quarter-3.68%
Sales3.37B P/S3.59 EPS this Y-1.42% Inst Trans4.56% Short Ratio5.07 Perf Half Y9.77%
Book/sh19.33 P/B3.76 EPS next Y0.90% ROA15.71% Short Interest1.17M Perf Year25.77%
Cash/sh5.87 P/C12.39 EPS next 5Y0.21% ROE21.79% 52W Range57.40 - 77.72 Perf YTD4.44%
Dividend Est.0.48 (0.67%) P/FCF35.06 EPS past 5Y20.07% ROI19.58% 52W High-6.50% Beta0.55
Dividend TTM0.48 (0.66%) Quick Ratio1.92 Sales past 5Y8.97% Gross Margin56.58% 52W Low26.60% ATR (14)1.13
Dividend Ex-DateJul 30, 2024 Current Ratio2.58 EPS Y/Y TTM19.59% Oper. Margin22.25% RSI (14)59.24 Volatility1.01% 1.14%
Employees25863 Debt/Eq0.07 Sales Y/Y TTM10.37% Profit Margin19.95% Recom2.90 Target Price73.40
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q34.74% Payout10.07% Rel Volume0.89 Prev Close71.69
Sales Surprise0.05% EPS Surprise6.37% Sales Q/Q11.42% EarningsMay 07 BMO Avg Volume230.06K Price72.67
SMA203.86% SMA501.77% SMA2003.71% Trades Volume204,067 Change1.37%
Date Action Analyst Rating Change Price Target Change
Jan-11-24Downgrade Jefferies Buy → Underperform
Aug-29-23Downgrade HSBC Securities Buy → Hold
May-18-23Downgrade Bernstein Outperform → Mkt Perform
Mar-17-23Upgrade BofA Securities Neutral → Buy
Jan-30-23Initiated JP Morgan Underweight
Nov-14-22Downgrade Credit Suisse Neutral → Underperform
Jan-03-22Resumed BofA Securities Neutral
Jul-27-21Downgrade Credit Suisse Outperform → Neutral
Feb-02-21Upgrade Barclays Equal Weight → Overweight $56 → $70
Sep-18-20Upgrade Investec Sell → Hold
Jun-03-24 01:05PM
May-28-24 09:53AM
May-22-24 12:16PM
07:11AM
May-21-24 10:05AM
09:40AM Loading…
May-09-24 09:40AM
May-08-24 01:55PM
01:12PM
09:01AM
May-07-24 12:54PM
10:31AM
May-03-24 08:00AM
Mar-22-24 07:00AM
Mar-20-24 09:40AM
Mar-19-24 07:00AM
09:40AM Loading…
Feb-28-24 09:40AM
Feb-05-24 09:50AM
Feb-01-24 11:01AM
09:03AM
Jan-31-24 09:44AM
Jan-30-24 02:03PM
06:19AM
05:38AM
Jan-29-24 05:50PM
Jan-03-24 06:00AM
Dec-14-23 07:49AM
Dec-06-23 07:00AM
Nov-02-23 09:40AM
Oct-30-23 07:38AM
Oct-29-23 01:08PM
02:13PM Loading…
Oct-27-23 02:13PM
01:50PM
Oct-26-23 12:00PM
Oct-04-23 12:45PM
Sep-26-23 09:35AM
Sep-18-23 12:45PM
Aug-31-23 12:45PM
Aug-10-23 07:00AM
Jul-28-23 08:02AM
Jul-27-23 10:30AM
Jul-26-23 12:31PM
Jul-12-23 10:25AM
Jun-09-23 09:45PM
Jun-08-23 09:54PM
11:14AM
Jun-06-23 07:18AM
Jun-05-23 07:00AM
Jun-04-23 03:51PM
May-16-23 10:22AM
May-11-23 09:58AM
May-10-23 11:43AM
09:21AM
May-08-23 01:28PM
May-05-23 07:17AM
Apr-21-23 07:15AM
Mar-20-23 07:00AM
Feb-27-23 03:04PM
06:00AM
Feb-08-23 08:50AM
Jan-31-23 06:25PM
Jan-30-23 06:51PM
Jan-27-23 01:36PM
07:03AM
Jan-26-23 12:55PM
Jan-20-23 06:30AM
Dec-19-22 08:00AM
Oct-31-22 11:01AM
Oct-11-22 07:57AM
Sep-07-22 01:28PM
Aug-17-22 10:16AM
Aug-02-22 09:45AM
Jul-29-22 04:28PM
01:24PM
Jul-27-22 03:26AM
Jul-22-22 06:17AM
Jul-08-22 11:48AM
Jul-05-22 03:30AM
Jun-24-22 09:45AM
09:09AM
07:30AM
Jun-14-22 02:51AM
May-27-22 10:15AM
May-24-22 01:40PM
May-20-22 09:50AM
Apr-20-22 12:41PM
Apr-05-22 06:52AM
Apr-01-22 08:00AM
Mar-27-22 01:09AM
Feb-09-22 09:17AM
Feb-03-22 09:33AM
Feb-02-22 04:15AM
Jan-31-22 01:10PM
09:38AM
Jan-04-22 06:18AM
Dec-15-21 01:49PM
Dec-14-21 12:20PM
Dec-09-21 11:47PM
03:18AM
12:50AM
Dec-08-21 09:00PM
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment focuses on manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API, which are the principal ingredients for finished pharmaceutical products. The Others segment includes the operations of the subsidiary of the company. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.